"We need a strong announcement involving contracts, m&as or revenues. The MC is too high still based on the initial promise so we need to start seeing some substantial news / results."
Q'ly out end of May; should show accelerating monthly revenues from February's low of approx $500k.
I'll be happy with that.
The next Q'ly will see further strong revenue growth off a low base, but still mainly generated from trials.
Note BranchOut only officially launched in March. Allowing 3-5 months for the trials indicates August onwards for hopefully a rash of announcements that trials have progressed into 12m+ contracts. Which btw is the month the company expects to be cash-flow break-even.
The Oct-Dec period is where the potential should really start to become graphic. Management have expectations of ending the calendar year with an annualised monthly run rate of USD$24m+.
So, in conclusion, you could get inpatient and hanker for a "strong announcement" in the short term to soothe those jangling nerves.
Or you could have patience and wait for the story to play out and be part of something potentially rather special.
1PG Price at posting:
$1.76 Sentiment: Buy Disclosure: Held
